B. Ditzler , E. Lashnits , K.M. Meurs , R.G. Maggi , M. Yata , P. Neupane , E.B. Breitschwerdt
{"title":"病媒传播的病原体和心脏 Striatin 基因型对患有致心律失常性右室心肌病的拳师犬存活率的影响","authors":"B. Ditzler , E. Lashnits , K.M. Meurs , R.G. Maggi , M. Yata , P. Neupane , E.B. Breitschwerdt","doi":"10.1016/j.jvc.2024.09.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction/Objectives</h3><div>Risk factors for severe disease in boxer dogs with arrhythmogenic right ventricular cardiomyopathy (ARVC) are not well understood. This study's objective was to determine whether Striatin genotype or canine vector-borne pathogen (CVBP) exposure/infection in boxer dogs with ARVC was associated with disease severity or survival.</div></div><div><h3>Animals</h3><div>Sixty-four client-owned, adult boxer dogs with ARVC were included in the study.</div></div><div><h3>Materials and Methods</h3><div>This was a prospective descriptive study. Disease severity was determined by echocardiography and Holter monitoring. Potential risk factors included CVBP exposure/infection (<em>Anaplasma</em> spp.<em>, Babesia</em> spp., <em>Bartonella</em> spp., <em>Borrelia burgdorferi</em>, <em>Dirofilaria immitis, Ehrlichia</em> spp., and <em>Rickettsia</em> spp.) and Striatin genotype.</div></div><div><h3>Results</h3><div>The median survival time after enrollment was 270 days (95% confidence interval [CI]: 226–798 days), and the median age at the time of death or censoring was 11 years (95% CI: 10.3–11.7 years). Striatin mutation genotype results included 31 homozygous-negative, 26 heterozygous-positive, and seven homozygous-positive boxer dogs. Ten boxer dogs had exposure to <em>Bartonella</em> spp., four to <em>Rickettsia,</em> two to <em>Ehrlichia</em> spp., and one to <em>Anaplasma</em> spp. Striatin homozygous–positive boxer dogs had a shorter median survival time (93 days vs. 373 days for heterozygous [P=0.010] and 214 days for homozygous negative [P=0.036]). Exposure/infection to CVBP was not associated with median survival time or age at the time of death.</div></div><div><h3>Discussion</h3><div>Striatin homozygous positive boxer dogs with ARVC had shorter survival times and were younger at the time of death. Exposure or infection with CVBP did not appear to influence survival time.</div></div><div><h3>Study Limitations</h3><div>Selection bias for more severe disease limited the ability to assess the relationship between CVBP infection/exposure and disease severity, and overall small sample size limited statistical power. Extracardiac disease and treatment protocols were not controlled.</div></div><div><h3>Conclusions</h3><div>Striatin genotype screening can be considered for prognostic information. Exposure/infection to CVBP appears unlikely to influence survival time for boxer dogs with ARVC.</div></div>","PeriodicalId":48788,"journal":{"name":"Journal of Veterinary Cardiology","volume":"56 ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The role of vector-borne pathogens and cardiac Striatin genotype on survival in boxer dogs with arrhythmogenic right ventricular cardiomyopathy\",\"authors\":\"B. Ditzler , E. Lashnits , K.M. Meurs , R.G. Maggi , M. Yata , P. Neupane , E.B. Breitschwerdt\",\"doi\":\"10.1016/j.jvc.2024.09.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction/Objectives</h3><div>Risk factors for severe disease in boxer dogs with arrhythmogenic right ventricular cardiomyopathy (ARVC) are not well understood. This study's objective was to determine whether Striatin genotype or canine vector-borne pathogen (CVBP) exposure/infection in boxer dogs with ARVC was associated with disease severity or survival.</div></div><div><h3>Animals</h3><div>Sixty-four client-owned, adult boxer dogs with ARVC were included in the study.</div></div><div><h3>Materials and Methods</h3><div>This was a prospective descriptive study. Disease severity was determined by echocardiography and Holter monitoring. Potential risk factors included CVBP exposure/infection (<em>Anaplasma</em> spp.<em>, Babesia</em> spp., <em>Bartonella</em> spp., <em>Borrelia burgdorferi</em>, <em>Dirofilaria immitis, Ehrlichia</em> spp., and <em>Rickettsia</em> spp.) and Striatin genotype.</div></div><div><h3>Results</h3><div>The median survival time after enrollment was 270 days (95% confidence interval [CI]: 226–798 days), and the median age at the time of death or censoring was 11 years (95% CI: 10.3–11.7 years). Striatin mutation genotype results included 31 homozygous-negative, 26 heterozygous-positive, and seven homozygous-positive boxer dogs. Ten boxer dogs had exposure to <em>Bartonella</em> spp., four to <em>Rickettsia,</em> two to <em>Ehrlichia</em> spp., and one to <em>Anaplasma</em> spp. Striatin homozygous–positive boxer dogs had a shorter median survival time (93 days vs. 373 days for heterozygous [P=0.010] and 214 days for homozygous negative [P=0.036]). Exposure/infection to CVBP was not associated with median survival time or age at the time of death.</div></div><div><h3>Discussion</h3><div>Striatin homozygous positive boxer dogs with ARVC had shorter survival times and were younger at the time of death. Exposure or infection with CVBP did not appear to influence survival time.</div></div><div><h3>Study Limitations</h3><div>Selection bias for more severe disease limited the ability to assess the relationship between CVBP infection/exposure and disease severity, and overall small sample size limited statistical power. Extracardiac disease and treatment protocols were not controlled.</div></div><div><h3>Conclusions</h3><div>Striatin genotype screening can be considered for prognostic information. Exposure/infection to CVBP appears unlikely to influence survival time for boxer dogs with ARVC.</div></div>\",\"PeriodicalId\":48788,\"journal\":{\"name\":\"Journal of Veterinary Cardiology\",\"volume\":\"56 \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Veterinary Cardiology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1760273424000936\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Cardiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1760273424000936","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
The role of vector-borne pathogens and cardiac Striatin genotype on survival in boxer dogs with arrhythmogenic right ventricular cardiomyopathy
Introduction/Objectives
Risk factors for severe disease in boxer dogs with arrhythmogenic right ventricular cardiomyopathy (ARVC) are not well understood. This study's objective was to determine whether Striatin genotype or canine vector-borne pathogen (CVBP) exposure/infection in boxer dogs with ARVC was associated with disease severity or survival.
Animals
Sixty-four client-owned, adult boxer dogs with ARVC were included in the study.
Materials and Methods
This was a prospective descriptive study. Disease severity was determined by echocardiography and Holter monitoring. Potential risk factors included CVBP exposure/infection (Anaplasma spp., Babesia spp., Bartonella spp., Borrelia burgdorferi, Dirofilaria immitis, Ehrlichia spp., and Rickettsia spp.) and Striatin genotype.
Results
The median survival time after enrollment was 270 days (95% confidence interval [CI]: 226–798 days), and the median age at the time of death or censoring was 11 years (95% CI: 10.3–11.7 years). Striatin mutation genotype results included 31 homozygous-negative, 26 heterozygous-positive, and seven homozygous-positive boxer dogs. Ten boxer dogs had exposure to Bartonella spp., four to Rickettsia, two to Ehrlichia spp., and one to Anaplasma spp. Striatin homozygous–positive boxer dogs had a shorter median survival time (93 days vs. 373 days for heterozygous [P=0.010] and 214 days for homozygous negative [P=0.036]). Exposure/infection to CVBP was not associated with median survival time or age at the time of death.
Discussion
Striatin homozygous positive boxer dogs with ARVC had shorter survival times and were younger at the time of death. Exposure or infection with CVBP did not appear to influence survival time.
Study Limitations
Selection bias for more severe disease limited the ability to assess the relationship between CVBP infection/exposure and disease severity, and overall small sample size limited statistical power. Extracardiac disease and treatment protocols were not controlled.
Conclusions
Striatin genotype screening can be considered for prognostic information. Exposure/infection to CVBP appears unlikely to influence survival time for boxer dogs with ARVC.
期刊介绍:
The mission of the Journal of Veterinary Cardiology is to publish peer-reviewed reports of the highest quality that promote greater understanding of cardiovascular disease, and enhance the health and well being of animals and humans. The Journal of Veterinary Cardiology publishes original contributions involving research and clinical practice that include prospective and retrospective studies, clinical trials, epidemiology, observational studies, and advances in applied and basic research.
The Journal invites submission of original manuscripts. Specific content areas of interest include heart failure, arrhythmias, congenital heart disease, cardiovascular medicine, surgery, hypertension, health outcomes research, diagnostic imaging, interventional techniques, genetics, molecular cardiology, and cardiovascular pathology, pharmacology, and toxicology.